Apixaban vs warfarin for HeartMate 3 LVAD
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests if the blood thinner apixaban (Eliquis) is as safe and effective as warfarin (Coumadin) for people with a HeartMate 3 LVAD heart pump. The goal is to find a simpler, more stable option for preventing blood clots.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a HeartMate 3 LVAD (a type of heart pump) that was placed at least 3 months ago.
- You are currently taking the blood thinner warfarin (Coumadin).
- You are 18 years or older.
- You are not allergic to apixaban (Eliquis).
- You are not using the LVAD as a temporary bridge to a heart transplant.
- You do not have severe kidney disease (eGFR less than 20).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if taking aspirin along with a standard blood thinner helps people with a HeartMate3 heart pump have fewer bleeding or clotting problems. It is for people who have had their pump for at least 3 months.
This trial tests apixaban (a blood thinner) to prevent stroke in people with atrial fibrillation or atrial flutter who have very poor kidney function or are on dialysis. If you qualify, you may help researchers find a safer way to lower stroke risk for this higher-risk group.
This study tests whether patients with an artificial heart pump (CH-VAD) can safely stop taking aspirin after surgery. Aspirin is often given to prevent blood clots, but this trial wants to see if it's really necessary for this specific pump.
This study tests if a slightly lower dose of the blood thinner warfarin can lower the risk of stomach or other bleeding, while still protecting against blood clots, in people who have a HeartMate 3 heart pump.
This trial tests whether a newer blood thinner, apixaban, works better than the standard warfarin for treating blood clots in the left ventricle after a heart attack. The goal is to see which medication is safer and more effective at preventing complications.
This trial tests whether patients who receive a special device to close a hole in the heart (to prevent stroke from irregular heartbeat) can safely take fewer blood-thinning medications afterward. The study compares taking a standard blood thinner for 3 months versus taking aspirin only, to see which approach works best with fewer bleeding risks.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.